#1 Clinical Trials Search in Europe

Ethambutol Hydrochloride

Ethambutol Hydrochloride has been extensively studied in clinical trials, particularly for its role in treating Mycobacterium Avium Complex (MAC) infections in AIDS patients. These trials have explored various combination therapies, dosing regimens, and efficacy comparisons with other drugs. The research aims to optimize treatment strategies for MAC, a significant opportunistic infection in immunocompromised individuals.

Table of Contents

What is Ethambutol Hydrochloride?

Ethambutol hydrochloride, also known by the brand name Myambutol[6], is an important antibiotic medication used primarily in the treatment of various mycobacterial infections. It is a key component in many treatment regimens for tuberculosis (TB) and other related conditions[1][2].

Conditions Treated with Ethambutol

Ethambutol hydrochloride is used to treat several conditions, including:

  • Mycobacterium Avium Complex (MAC) Infection: This is a type of bacterial infection that commonly affects people with weakened immune systems, such as those with AIDS. Ethambutol is often used in combination with other drugs to treat or prevent MAC[1][2].
  • Tuberculosis (TB): Ethambutol is a standard component of many TB treatment regimens, especially for patients who are also HIV-positive[10].
  • HIV-related Infections: In patients with HIV/AIDS, ethambutol is often used to treat or prevent opportunistic infections caused by mycobacteria[3].

Ethambutol in Combination Therapy

Ethambutol is rarely used alone. Instead, it’s typically part of a combination therapy approach. Some common combinations include:

  • Ethambutol + Clarithromycin: This combination is often used to treat MAC infections in AIDS patients[3].
  • Ethambutol + Rifabutin: Used in some regimens for preventing or treating MAC bacteremia in AIDS patients[4].
  • Ethambutol + Azithromycin: Another combination used for treating disseminated MAC infection in AIDS patients[5].
  • Ethambutol + Isoniazid + Rifampin + Pyrazinamide: This four-drug combination is a standard initial treatment for tuberculosis[10].

These combinations are designed to increase effectiveness and reduce the risk of drug resistance developing in the bacteria.

Dosage and Administration

The dosage of ethambutol can vary depending on the specific condition being treated, the patient’s weight, and other factors. Generally, it is taken orally (by mouth) once daily. Here’s an example of a typical dosing schedule based on weight[6]:

  • 40-55 kg: 800 mg (two 400 mg tablets)
  • 56-75 kg: 1,200 mg (three 400 mg tablets)
  • 76-90 kg: 1,600 mg (four 400 mg tablets)
  • Over 90 kg: 1,600 mg (four 400 mg tablets)

It’s important to note that these are general guidelines, and your doctor will determine the appropriate dose for your specific situation.

Potential Side Effects and Safety Considerations

While ethambutol is generally well-tolerated, it can cause side effects. One of the most significant potential side effects is vision changes. Ethambutol can affect the optic nerve, potentially causing decreased visual acuity or color vision changes. For this reason, regular eye exams are often recommended for patients taking ethambutol[6].

Other potential side effects may include nausea, vomiting, abdominal pain, and in rare cases, liver problems. It’s important to report any unusual symptoms to your healthcare provider promptly.

Ongoing Research and Clinical Trials

Researchers continue to study ethambutol to better understand its effects and optimize its use. Some areas of ongoing research include:

  • Pharmacokinetics in Different Populations: Studies are examining how factors like weight and obesity affect how the body processes ethambutol[6].
  • Combination Therapies: Researchers are investigating new combinations of drugs that include ethambutol for treating various mycobacterial infections[7].
  • Dosing Strategies: Studies are exploring different dosing regimens to maximize effectiveness while minimizing side effects[9].

These ongoing studies aim to improve our understanding of ethambutol and enhance its use in treating various infections.

Aspect Details
Primary Use Treatment and prevention of Mycobacterium Avium Complex (MAC) in AIDS patients
Common Combinations Clarithromycin, Azithromycin, Rifabutin, Clofazimine
Administration Oral, typically daily dosing
Duration Varies, often long-term (12-48 weeks or more)
Key Outcomes Measured Reduction in MAC bacteremia, time to sterile blood culture, survival rates
Safety Considerations Tolerability, adverse events, drug interactions
Special Populations AIDS patients with low CD4 counts, obese individuals (in some studies)
Dosing Factors Weight-based in some trials, adjusted for blood levels in others

FAQ

  • What is Ethambutol Hydrochloride used for in these clinical trials? Ethambutol Hydrochloride is primarily used in these trials to treat or prevent Mycobacterium Avium Complex (MAC) infections in AIDS patients. It's often used in combination with other antibiotics to improve treatment efficacy.
  • How is Ethambutol Hydrochloride typically administered in these trials? In most trials, Ethambutol Hydrochloride is administered orally, often daily, for extended periods. The dosage may vary based on the patient's weight and is sometimes adjusted to maintain minimum blood levels of the drug.
  • What other drugs is Ethambutol Hydrochloride commonly combined with in these trials? Ethambutol Hydrochloride is frequently combined with drugs such as clarithromycin, azithromycin, rifabutin, and clofazimine. The specific combinations vary between trials, aiming to find the most effective treatment regimen.
  • What are the main goals of these clinical trials involving Ethambutol Hydrochloride? The main goals include assessing the drug's efficacy in reducing MAC bacteremia, evaluating its safety and tolerability, comparing different combination therapies, and determining optimal dosing strategies for MAC treatment in AIDS patients.
  • Are there any studies looking at Ethambutol Hydrochloride's effectiveness in non-AIDS patients? Yes, one study examines the effect of weight and obesity on Ethambutol drug concentrations in healthy volunteers. This research aims to understand how body mass index (BMI) affects the drug's clearance from the blood.

Ongoing Clinical Trials on Ethambutol Hydrochloride

  • Study evaluating blood biomarkers for diagnosis and monitoring treatment in patients with pulmonary tuberculosis using isoniazid, rifampicin, pyrazinamide, and ethambutol combination

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on High-Dose Rifampicin Safety for Adults with Complex Tuberculosis Using Isoniazid, Pyrazinamide, and Ethambutol Combination

    Recruiting

    1 1 1
    Investigated drugs:
    The Netherlands Spain

  • Study Comparing Clarithromycin and Azithromycin for Treating Mycobacterium Avium Complex Lung Infections in Adults

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Amikacin for Treating Mycobacterium Xenopi Lung Infection in Patients Using Amikacin and Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study on the Effects of Amikacin Liposome Inhalation, Azithromycin, and Ethambutol in Adults with Newly Diagnosed Nontuberculous Mycobacterial Lung Infection

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Denmark France Germany Greece +5

  • Study on the Effectiveness and Safety of High-Dose Rifampicin, Moxifloxacin, and Linezolid for Patients with Pulmonary Tuberculosis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Mycobacterium Avium Complex (MAC): A group of bacteria that can cause life-threatening infections in people with weakened immune systems, such as those with AIDS.
  • Bacteremia: The presence of bacteria in the blood, which can be a serious condition, especially in immunocompromised individuals.
  • Prophylaxis: Preventive treatment to stop a disease from occurring. In these trials, it refers to using drugs to prevent MAC infections in AIDS patients.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Colony-forming units (CFUs): A measure used to estimate the number of viable bacteria in a sample. Reducing CFUs is a goal in treating bacterial infections.
  • Body Mass Index (BMI): A measure that uses your height and weight to work out if your weight is healthy. It's used in some trials to categorize participants.
  • Clearance: The rate at which a drug is removed from the blood or body. In some trials, researchers study how factors like obesity affect drug clearance.

References

  1. https://clinicaltrials.gov/study/NCT00002343
  2. https://clinicaltrials.gov/study/NCT00001039
  3. https://clinicaltrials.gov/study/NCT00002331
  4. https://clinicaltrials.gov/study/NCT00002101
  5. https://clinicaltrials.gov/study/NCT00002140
  6. https://clinicaltrials.gov/study/NCT01048697
  7. https://clinicaltrials.gov/study/NCT05966688
  8. https://clinicaltrials.gov/study/NCT00001047
  9. https://clinicaltrials.gov/study/NCT00002192
  10. https://clinicaltrials.gov/study/NCT00000950